Dassault Systèmes SE Stock
Price
Target price
€37.30
€37.30
-1.060%
-0.4
-1.060%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Dassault Systèmes SE Stock
We can see a decrease in the price for Dassault Systèmes SE. Compared to yesterday it has lost -€0.400 (-1.060%).
So far the community has only identified positive things for Dassault Systèmes SE stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Dassault Systèmes SE in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dassault Systèmes SE vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dassault Systèmes SE | -1.060% | -4.113% | 1.414% | -10.584% | -15.868% | 0.000% | 41.021% |
| Cap Gemini S.A. | -4.070% | -12.177% | -6.331% | 11.465% | -1.526% | 24.023% | 88.242% |
| CrowdStrike Holdings Inc | -0.790% | -10.773% | 2.102% | 104.565% | 25.265% | 59.961% | - |
| Gartner Inc. | 0.390% | -4.398% | -0.973% | 20.081% | -5.380% | 102.565% | - |
News
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced today that it has been selected by Lexicon Pharmaceuticals, Inc. to
Medidata Selected by Worldwide Clinical Trials to Accelerate Trials and Transform Patient Experience
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an expansion of its relationship with Worldwide Clinical Trials
JLR and Dassault Systèmes Extend Partnership, Deploying the 3DEXPERIENCE Platform for All Vehicle Programs Worldwide
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced that it has extended its long-term strategic partnership with JLR for five years, heralding a new era of digital